Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: explorato
8 days ago
- #biomarkers
- #durvalumab
- #endometrial cancer
- Exploratory analyses of the DUO-E/GOG-3041/ENGOT-EN10 trial focused on biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in mismatch repair proficient (pMMR) endometrial cancer.
- The trial demonstrated significant progression-free survival (PFS) benefits with durvalumab-based treatments compared to carboplatin/paclitaxel alone in advanced/recurrent endometrial cancer.
- Biomarkers such as PD-L1 expression, BRCA1/BRCA2 mutations, homologous recombination repair genes, DNA polymerase epsilon, and TP53 mutations were evaluated in 486 out of 575 pMMR patients, with 84% positive for at least one biomarker.
- PD-L1 positivity (67%) and TP53 mutations (59%) were the most prevalent biomarkers in the pMMR subpopulation.
- Endometrioid (52%) and serous (27%) histologies were the most common tumor types in the biomarker-known subpopulation.
- Exploratory analyses showed improved PFS hazard ratios for durvalumab and durvalumab plus olaparib arms across multiple biomarker and histological subgroups, with durvalumab plus olaparib showing greater benefit in most subgroups.
- The pMMR subpopulation exhibited high heterogeneity with frequent biomarker and histology overlap.
- Consistent with the primary analysis, durvalumab plus olaparib enhanced PFS benefits over durvalumab alone across various biomarker and histological subgroups.